November 03, 2025

Metastatic ER-Positive, HER2-Negative Breast Cancer: Novel Treatment Combination Improves Progression-Free Survival

Patients with ER-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival (PFS) when treated with an oral combination regimen that includes giredestrant, ...

The ASCO Post

October 30, 2025

Study Shows Potential Benefits of AI-Assisted Classification in HER2-Low and HER2-Ultralow Breast Cancer

With the approval of HER2-targeted antibody-drug conjugate options for treating patients with breast cancer across different HER2 expression levels, accurate assessment of HER2 expression has become m...

The ASCO Post

October 29, 2025

AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis

A U.S. Food and Drug Administration (FDA)​​-cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective eval...

The ASCO Post

October 29, 2025

AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative

Panoramic photoacoustic computed tomography (PACT) with machine learning assistance could be a safe, noninvasive, and sensitive alternative to mammography, ultrasound, and MRI for breast cancer screen...

The ASCO Post

October 28, 2025

AI Shear Wave Elastography Model for Diagnosing Breast Cancer in BI-RADS 3 or 4 Masses

In a study (INSPiRED 006) reported in the Journal of Clinical Oncology, Cai et al found that an artificial intelligence–guided shear wave elastography (AI-SWE) model provided accuracy similar to exper...

The ASCO Post

October 19, 2025

ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.

Dana-Farber

October 18, 2025

Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.

Dana-Farber

October 13, 2025

Breast, Lung, and Bladder Cancer Phase 3 Trials led by Dana-Farber Presented at ESMO Congress 2025

Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.

Dana-Farber

October 08, 2025

Breast Cancer Research: Updates for 2025

Novel treatment protocols are demonstrating significant improvements in overall survival and progression-free survival for breast cancer patients while targeted therapies continue to expand treatment options

Baptist Health South Florida